Establishment of a prognostic model to predict chemotherapy response and identification of RAC3 as a chemotherapeutic target in bladder cancer

被引:3
作者
Chen, Yuelong [1 ,2 ,3 ]
Huang, Ming [1 ,2 ]
Lu, Junlin [1 ,2 ]
Zhang, Qiang [1 ,2 ]
Wu, Jilin [1 ,2 ]
Peng, Shengmeng [1 ,2 ]
Chen, Siting [2 ]
Zhang, Yangjie [1 ,2 ]
Cheng, Liang [1 ,2 ]
Lin, Tianxin [1 ,2 ,4 ]
Chen, Xu [1 ,2 ,4 ,5 ]
Huang, Jian [1 ,2 ,4 ,5 ]
机构
[1] Sun Yat sen Univ, Sun Yat sen Mem Hosp, Dept Urol, Guangzhou, Peoples R China
[2] Sun Yat sen Univ, Sun Yat sen Mem Hosp, Guangdong Prov Key Lab Malignant Tumor Epigenet &, Guangzhou, Peoples R China
[3] Kunming Med Univ, Affiliated Hosp 1, Dept Urol, Kunming, Peoples R China
[4] Guangdong Prov Clin Res Ctr Urol Dis, Guangzhou, Peoples R China
[5] Sun Yat sen Univ, Sun Yat sen Mem Hosp, Dept Urol, Guangzhou 510120, Guangdong, Peoples R China
基金
中国博士后科学基金; 中国国家自然科学基金;
关键词
bladder cancer; chemotherapy; predictive signature; RAC3; therapy target; RHO GTPASES; CELLS; EXPRESSION; PROLIFERATION; MULTICENTER; SENSITIVITY; METASTASIS; RECURRENCE; RESISTANCE; APOPTOSIS;
D O I
10.1002/tox.23860
中图分类号
X [环境科学、安全科学];
学科分类号
08 ; 0830 ;
摘要
Cisplatin-based chemotherapy is considered the primary treatment option for patients with advanced bladder cancer (BCa). However, the objective response rate to chemotherapy is often unsatisfactory, leading to a poor 5-year survival rate. Furthermore, current strategies for evaluating chemotherapy response and prognosis are limited and inefficient. In this study, we aimed to address these challenges by establishing a chemotherapy response type gene (CRTG) signature consisting of 9 genes and verified the prognostic value of this signature using TCGA and GEO BCa cohorts. The risk scores based on the CRTG signature were found to be associated with advanced clinicopathological status and demonstrated favorable predictive power for chemotherapy response in the TCGA cohort. Meanwhile, tumors with high risk scores exhibited a tendency toward a "cold tumor" phenotype. These tumors showed a low abundance of T cells, CD8+ T cells and cytotoxic lymphocytes, along with a high abundance of cancer-associated fibroblasts. Moreover, they displayed higher mRNA levels of these immune checkpoints: CD200, CD276, CD44, NRP1, PDCD1LG2 (PD-L2), and TNFSF9. Furthermore, we developed a nomogram that integrated the CRTG signature with clinicopathologic risk factors. This nomogram proved to be a more effective tool for predicting the prognosis of BCa patients. Additionally, we identified Rac family small GTPase 3 (RAC3) as a biomarker in our model. RAC3 was found to be overexpressed in chemoresistant BCa tissues and enhance the chemotherapeutic resistance of BCa cells in vitro and in vivo by regulating the PAK1-ERK1/2 pathway. In conclusion, our study presents a novel CRTG model for predicting chemotherapy response and prognosis in BCa. We also highlight the potential of combining chemotherapy with immunotherapy as a promising strategy for chemoresistant BCa and that RAC3 might be a latent target for therapeutic intervention.
引用
收藏
页码:509 / 528
页数:20
相关论文
共 56 条
[41]   Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries [J].
Sung, Hyuna ;
Ferlay, Jacques ;
Siegel, Rebecca L. ;
Laversanne, Mathieu ;
Soerjomataram, Isabelle ;
Jemal, Ahmedin ;
Bray, Freddie .
CA-A CANCER JOURNAL FOR CLINICIANS, 2021, 71 (03) :209-249
[42]   Benzyl isothiocyanate promotes miR-99a expression through ERK/AP-1-dependent pathway in bladder cancer cells [J].
Tsai, Te-Fu ;
Chen, Po-Chun ;
Lin, Yi-Chia ;
Chou, Kuang-Yu ;
Chen, Hung-En ;
Ho, Chao-Yen ;
Lin, Ji-Fan ;
Hwang, Thomas I-S. .
ENVIRONMENTAL TOXICOLOGY, 2020, 35 (01) :47-54
[43]   Cisplatin contributes to programmed death-ligand 1 expression in bladder cancer through ERK1/2-AP-1 signaling pathway [J].
Tsai, Te-Fu ;
Lin, Ji-Fan ;
Lin, Yi-Chia ;
Chou, Kuang-Yu ;
Chen, Hung-En ;
Ho, Chao-Yen ;
Chen, Po-Chun ;
Hwang, Thomas I-Sheng .
BIOSCIENCE REPORTS, 2019, 39
[44]   Somatic ERCC2 Mutations Correlate with Cisplatin Sensitivity in Muscle-Invasive Urothelial Carcinoma [J].
Van Allen, Eliezer M. ;
Mouw, Kent W. ;
Kim, Philip ;
Iyer, Gopa ;
Wagle, Nikhil ;
Al-Ahmadie, Hikmat ;
Zhu, Cong ;
Ostrovnaya, Irina ;
Kryukov, Gregory V. ;
O'Connor, Kevin W. ;
Sfakianoss, John ;
Garcia-Grossman, Ilana ;
Kim, Jaegil ;
Guancial, Elizabeth A. ;
Bambury, Richard ;
Bahl, Samira ;
Gupta, Namrata ;
Farlow, Deborah ;
Qu, Angela ;
Signoretti, Sabina ;
Barletta, Justine A. ;
Reuter, Victor ;
Boehm, Jesse ;
Lawrence, Michael ;
Getz, Gad ;
Kantoff, Philip ;
Bochner, Bernard H. ;
Choueiri, Toni K. ;
Bajorin, Dean F. ;
Solit, David B. ;
Gabriel, Stacey ;
D'Andrea, Alan ;
Garraway, Levi A. ;
Rosenberg, Jonathan E. .
CANCER DISCOVERY, 2014, 4 (10) :1140-1153
[45]   RAC3 is a pro-migratory co-activator of ERα [J].
Walker, M. P. ;
Zhang, M. ;
Le, T. P. ;
Wu, P. ;
Laine, M. ;
Greene, G. L. .
ONCOGENE, 2011, 30 (17) :1984-1994
[46]   CD276 expression enables squamous cell carcinoma stem cells to evade immune surveillance [J].
Wang, Cheng ;
Li, Yang ;
Jia, Lingfei ;
Kim, Jin Koo ;
Li, Jiong ;
Deng, Peng ;
Zhang, Wuchang ;
Krebsbach, Paul H. ;
Wang, Cun-Yu .
CELL STEM CELL, 2021, 28 (09) :1597-+
[47]   The TNF Receptor Superfamily in Co-stimulating and Co-inhibitory Responses [J].
Ward-Kavanagh, Lindsay K. ;
Lin, Wai Wai ;
Sedy, John R. ;
Ware, Carl F. .
IMMUNITY, 2016, 44 (05) :1005-1019
[48]   Phase I Trial of Trametinib with Neoadjuvant Chemoradiation in Patients with Locally Advanced Rectal Cancer [J].
Wu, Christina ;
Williams, Terence M. ;
Robb, Ryan ;
Webb, Amy ;
Wei, Lai ;
Chen, Wei ;
Mikhail, Sameh ;
Ciombor, Kristen K. ;
Cardin, Dana B. ;
Timmers, Cynthia ;
Krishna, Somashekar G. ;
Arnold, Mark ;
Harzman, Alan ;
Abdel-Misih, Sherif ;
Roychowdhury, Sameek ;
Bekaii-Saab, Tanios ;
Wuthrick, Evan .
CLINICAL CANCER RESEARCH, 2020, 26 (13) :3117-3125
[49]   NEDD4L inhibits migration, invasion, cisplatin resistance and promotes apoptosis of bladder cancer cells by inactivating the p62/Keap1/Nrf2 pathway [J].
Wu, Qi ;
Zhang, Huijiang ;
You, Shengjie ;
Xu, Zhaoyu ;
Liu, Xiang ;
Chen, Xuedong ;
Zhang, Weili ;
Ye, Junjie ;
Li, Peng ;
Zhou, Xiaoqing .
ENVIRONMENTAL TOXICOLOGY, 2023, 38 (07) :1678-1689
[50]   NONO Inhibits Lymphatic Metastasis of Bladder Cancer via Alternative Splicing of SETMAR [J].
Xie, Ruihui ;
Chen, Xu ;
Cheng, Liang ;
Huang, Ming ;
Zhou, Qianghua ;
Zhang, Jingtong ;
Chen, Yuelong ;
Peng, Shengmeng ;
Chen, Ziyue ;
Dong, Wen ;
Huang, Jian ;
Lin, Tianxin .
MOLECULAR THERAPY, 2021, 29 (01) :291-307